Medicine Dr. Kawa Lecture 4 - Treatment of asthma :

Similar documents
ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

Lecture Notes. Chapter 3: Asthma

Asthma. chapter 7. Overview

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness

Respiratory Pharmacology

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Medications Affecting The Respiratory System

31 - Respiratory System

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Significance. Asthma Definition. Focus on Asthma

Asthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital

기관지확장제와기관지천식 치료에쓰이는약물 이종호 한림의대약리학교실

Pharmacology of drugs used in bronchial asthma & COPD

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

Management of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Management of acute asthma in children in emergency department. Moderate asthma

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

Drugs acting on the respiratory tract

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

BNF CHAPTER 3: RESPIRATORY

Foundations of Pharmacology

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus

Respiratory Pharmacology. Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France

ASTHMA IN THE PEDIATRIC POPULATION


Bronchial Asthma and COPD

control in the lowest dose providing adequate Maintain high dose ICS Use daily steroid tablet dose Consider trials of: Increasing ICS up to

GUIDE LINE SUMMARY THE DIAGNOSIS AND TREATMENT OF ADULT ASTHMA BEST PRACTICE EV I DENCE-BASED KEY MESSAGES. Diagnosis.

Management of acute severe asthma in adults in general practice. Moderate asthma Acute severe asthma Life-threatening asthma INITIAL ASSESSMENT

Pathology of Asthma Epidemiology

British Guideline on the Management of Asthma

In the name of God. Asthma

FIGURE 17. USUAL DOSAGES FOR LONG-TERM CONTROL MEDICATIONS*

Objectives. Asthma in Primary Care. Definition. Epidemiology. Pathophysiology

Exacerbations. Ronald Dahl, Aarhus University Hospital, Denmark

Asthma. Definition. Symptoms

GUIDELINES LET S TALK ABOUT THE ASTHMA ...MADE MORE PRACTICAL GUIDELINES FOR PRACTICE...

Asthma Guidelines and Pharmacological Treatment. Dr James Wilkinson

Pharmacology Drugs of Respiratory system. Drugs acting on respiratory system. Dr. Ahmad Al-Zohyri Lec. 11

ASTHMA BEST PRACTICES FOR SCHOOL NURSES. School Nurses November 2015

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Title Protocol for the Management of Asthma

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL

PHARMACOLOGICAL PROBLEMS

A New Look At Asthma

Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015

Asthma Management for the Athlete

Asthma/COPD. Asthma synopsis. chronic inflammation of bronchial airways bronchi lining bronchi muscles mucus

Estimated date of first patient enrolled Q III/IV Estimated date of last patient completed Q3 2015

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

1. ASTHMA 1. Eve A. Kerr, MD, MPH and Kenneth A. Clark, MD, MPH

Bronchospasm & SOB. Kim Kilmurray Senior Clinical Teaching Fellow

Asthma Medications: Information for Children and Families. What You Need to Know about Medicines for Asthma

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

Respiratory Health. Asthma and COPD

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication

Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet

patient group direction

Monocast Description Indications

Antiallergics and drugs used in anaphylaxis

Asthma/wheeze management plan

Emily DiMango, MD Asthma II

2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information

Clinical Guideline for the Diagnosis, Evaluation, and Management of Adults and Children with Asthma

RESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED

Adult Asthma Clinical Practice Guideline Summary

Respiratory system. 1. Asthma acute exacerbations. Contents:

3 RESPIRATORY SYSTEM

Basic mechanisms disturbing lung function and gas exchange

Sample. Affix patient label within this box.

Respiratory system. Contents: 1. Asthma acute exacerbations

Allwin Mercer Dr Andrew Zurek

The proposal is to add text/statements in red and to delete text/statements with strikethrough: POLICY

Emergency Asthma Care

10/6/2014. Tommy s Story: An Overview of Asthma Mangement. Disclosure. Objectives for this talk.

beclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))

Asthma By Mayo Clinic staff

COPD. Breathing Made Easier

Global Initiative for Asthma (GINA) What s new in GINA 2015?

Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation

Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)

Recurrent wheezing illnesses 24.9% Similar to Australia Above global averages

Decramer 2014 a &b [21]

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)

Asthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,

Report generated from BNF provided by FormularyComplete ( Accessed Formulary Status. TA Number. Section.

Asthma- THE most common Pediatric Disease JENNIFER MCDANIEL, RRT- NPS

The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma

Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders

Transcription:

Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Avoiding allergens. Hyposensitization :Subcutaneous injections of inially very small, but gradually increasing doses of allergens (desensitization or immunotherapy ). Drugs. Drug treatment : Can be divided in to 2 general categories : Quick relief medications : Drugs that act as relaxants of tracheobronchial smooth muscle ; (bronchodilators ) : β- adrenergic agonists, methylxonthines & anticholinergics. Long term control medications (Agents that prevent &/or reverse inflammation ) : glucocorticoids, leukotriene inhibitors & receptor antagonists, cromolyn sodium, nedocromils 1- Adrenergic stimulants: Short acting β-adrenergic(β2 selective) agonist: Salbutamol, Terbutaline, Metaproterenol, Pirbuterol, bitolterol. B- Long acting β-adrenergic(bselective)agents: salmeterol, fenoterol & formoterol C- Other adrenergic agonists : Catecholamines : adrenaline. 2-Methylxanthines(phosphodiesterase inhibitor ) : Theophylline 3-Anticholinergic agent: Ipratrupium bromide and atropin. glucocorticoids : For treatment of asthma it is available as inhalation, tablets, syrup & injections. Inhaled corticosteroid : -Preparations available are :beclomethasone, budesonide, flunisolide, fluticasone,triamcinolone. Side effects of inhaled steroid : oral candidates, glossitis, sore throat, hoarseness,dysphonia, increase systemic absorption with large doses of inhaled steroid (produce adrenal suppression, cataract, decrease growth in children.). 5-mast cell stabilizing agents: Cromolyn sodium & Nedocromil sodium. 1 P a g e

6-Antileukotrienes : Zafirlukast & Montelukast ( leukotriene receptor antagonist ) Zileuton (inhibitor of leukotriene synthesis ). 7- Antihistamines : Astemizole &Terfenadine 8- Ketotifen : 9-Other agents : Steroid dependent pt. might benefit from the use of immunosuppressant agents (used as steroid sparing agents),like : Methotrexate, Gold salt, & cyclosporine. Methotrexate, Gold salt may produce lung toxicity. Have limited role in the manegement off asthma. Not used as standered therapy for asthma. Omalizumab MECHANISM OF ACTION Omalizumab is an IgG monoclonal antibody which inhibits IgE binding to the IgE receptor on mast cells and basophils. By decreasing bound IgE, the activation and release of mediators in the allergic response (early and late phase) is limited. Long-term treatment in patients with allergic asthma showed a decrease in asthma exacerbations and corticosteroid usage. USE Treatment of moderate-to-severe, persistent allergic asthma not adequately controlled with inhaled corticosteroids CONTRAINDICATIONS Hypersensitivity to omalizumab & in status asthmaticus ADMINISTRATION For SubQ injection only Quick-Relief Used in acute episodes Generally short-acting beta 2 2agonists How to Use a Spray Inhaler Inhalers and Spacers Spacers can help patients who have difficulty with inhaler use and can reduce potential for adverse effects from medication. Nebulizer Machine produces a mist of the medication Used for small children or for severe asthma episodes 2 P a g e

Treatment of episodic asthma : Mild & infrequent episodes can be controlled by salbutamol inhaler. In pt. with more frequent episodes add sodium cromoglicate & beclomethasone inhaler. Treatment of exercise induced asthma Common in children &young adults,give 2 doses of salbutamol inhaler few minutes befor exercise, if not effective then add sodium cromoglicate & beclomethasone inhaler. Treatment of chronic persistent asthma : Step 1 : occasional use of inhaled short acting β2 agonist. As salbutamol or terbutaline,used by inhalation as required. If the pt. is using β2 agonist more than once daily, move to step 2 Step 2 :low dose inhaled steroid. Inhaled salbutamol is used as required + regular inhaled steroid (beclomethasone) up to 800 microgram daily. Step 3 : high dose inhaled steroids or low dose inhaled steroids + long acting inhaled β2 agonist. Inhaled salbutamol is used as required +inhaled steroid in dose range 800-2000 microgram daily. alternatively a long acting β2 agonist as salmeterol 50 microgram 12-hourly, or a sustainedrelease theophylline may be added. Step 4 : high dose inhaled steroids & regular bronchodilaters. Inhaled salbutamol is used as required + inhaled corticosteroid (800 2000 microgram dail ) + one or more of the following (as therapeutic trial ) : Inhaled long acting B2 agonist ( salmeterol ). Leukotriene recepror antagonist (montelukast ). Inhaled ipratropium bromide. Long acting oral B2 agonist( sustained release salbutamol or terbutaline preparations ). Sodium cromoglicate. Step 5 : addition of regular oral steroid therapy. Step 4 treatment is given +regular prednisolone tablets prescribed in the lowest amount necessary to control symptoms as a single daily dose in the morning. Occationally you can increase a step (step up) to control exacerbetions. You can decrease a step (step down) if good symptom control for 3 months or more. Only think of withdrawing anti inflammatory treatment if pt. well for at least 6 months. In general it is better to start with a treatment regimen which is likely to achieve disease control rapidly,& then step down, rather than to start with inadequate treatment & then have to step up. Management of acute sever asthma (status asthmaticus ): The aims of management are to prevent death & to restore pulmonary function as quick as possible. 3 P a g e

We should assess the pt. for the features of severity. According to the severity we can classified sever asthma in to : Acute sever asthma. Life threatening asthma. Near fatal asthma. Features of acute sever asthma : PEF< 50% of expected (<200 L/min). Respiratory rate >25 /min. Heart rate >110 beat /min. Inability to complete sentences in one breath. Features of life threatening asthma : Unrecordable PEF (<100 L/min). Pa O 2 < 8 kpa (especially if being treated with O 2 ). Silent chest. Cyanosis. Bradycardia or arrhythmias. Hypotention. Exhaustion. Confution. Coma. Features 0f near fatal asthma : Increase PaCO2 & / or Requirement for mechanical ventillation. Immediate treatment for acute sever asthma : 1-Oxygen: should be given at the highest concentration available ( usually 60 % ). Then the concentration adjusted according to the arterial blood gas measurement (PaO2 should be maintained > 9 kpa ). 2-High dose inhaled B2 agonist : B2 agonist should be nebulized using O2. Salbutamol 2.5 5 mg. or Terbutaline 5-10 mg. given initially & can be repeated within 30 min.if necessary. 3-Systemic corticosteroid: IV Hydrocortisone 200 mg. or oral Prednisolone 30-60mg Subsequent management of acute sever asthma If features of severity persist you should continue the management as following: 4 P a g e

1-Close monitoring & continue O2 therapy. 2-Continue nebulized B2 agonist : every 15-30 min ( reduce to 4 hourly once clear clinical response) 3-Ipratropium bromide 0.5 mg. should be added to the nebulized B2 agonist. 4-Continue systemic steroid : Hydrocortisone 200mg. IV. 6 hourly. 5-Magnesium sulphate : 25 mg /kg. IV. 6- Aminophylline IV. 7- Mechanical ventillation. Indications for assisted ventillation in acute sever asthma. Coma. 2-Respiratory arrest. 3-Exhaustion, Confution, Drowsiness. 4-Deterioration of arterial blood gas tention despite optimal therapy : -PaO2 < 8 kpa & falling. -PaCO2 > 6 kpa &rising. -PH low & falling. Monitoring of Treatment PEF recording should be made every 15-30 min. then PEF chart 4-6 hourly during hospital stay. 2-Repeated measurment of arterial blood gas tension or using pulse oxymetry. Managing Asthma: Peak Expiratory Flow (PEF) Meters Allows patient to assess status of his/her asthma Prognosis of asthma -The prognosis of individual asthma attacks is generally good. Complete remission of asthma is relatively common in children ( episodic asthma ), as many as 25% remain asymptomatic from adolescence onward. In adults ( chronic asthma ), prolonged remission of asthma symptoms are less common. Patients older than 65 years tend to have sever asthma that infrequently goes into remission, in these patients asthma is less reversible. There is occationally a fatal outcome especially if treatment is inadequate or delayed. -Atopic asthma is usually worse in the summer( heavely exposed to allergens ). -Chronic asthma is usually worse in the winter (increase frequency of viral infection 5 P a g e